Skip to main content

Fleqsuvy FDA Approval History

FDA Approved: Yes (First approved February 4, 2022)
Brand name: Fleqsuvy
Generic name: baclofen
Dosage form: Oral Suspension
Company: Azurity Pharmaceuticals, Inc.
Treatment for: Spasticity

Fleqsuvy (baclofen) is an oral suspension formulation of baclofen for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.

Development timeline for Fleqsuvy

Feb  7, 2022Approval FDA Approves Fleqsuvy (baclofen oral suspension) for the Treatment of Spasticity

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.